Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 18, 2025, the company has repurchased a total of 549,627 ordinary fully paid securities, with an additional 200,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily providing pathology services. The company focuses on delivering diagnostic testing services across Australia, catering to a wide range of healthcare needs.
Average Trading Volume: 1,000,002
Technical Sentiment Signal: Sell
Current Market Cap: A$528.6M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.